FEATURES


Viewpoints

Black Women Disproportionately Affected by Early-Stage Breast Cancer

Black Women Disproportionately Affected by Early-Stage Breast Cancer

Even with early diagnosis, there appears to be a disproportionate toll from breast cancer in black women.

Surveillance Until Rituximab Retreatment Does Not Increase Anxiety in Non-Hodgkin Lymphoma

Surveillance Until Rituximab Retreatment Does Not Increase Anxiety in Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma relapse is not a cause for increased anxiety if recurrence is quickly addressed with well tolerated therapy.

Feature Articles

Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer

Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer

New developments in metastatic castration-resistant prostate cancer (mCRPC) have resulted in several new therapies.

European Society for Medical Oncology (ESMO) Renal Cell Carcinoma Practice Guidelines

European Society for Medical Oncology (ESMO) Renal Cell Carcinoma Practice Guidelines

ESMO guidelines account for new criteria in renal cell carcinoma, providing guidance on recommended therapies as new data and kinase inhibitors have emerged.

Multiple myeloma: Optimal management and long-term disease control

Multiple myeloma: Optimal management and long-term disease control

[Blood and Lymphatic Cancer: Targets and Therapy] Myeloma displays considerable heterogeneity and, over time, control of disease can be lost. New strategies to combat myeloma incorporate risk stratification to provide more individualized therapy.

Slideshows

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed follicular non-Hodgkin lymphoma (FL).

Table of Contents

Slide 3: Indication, Dosage, ...

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide ...

From the Advisory Board

Reflecting on Treatment Strategies for Acute Leukemia

Reflecting on Treatment Strategies for Acute Leukemia

Leukemia is sometimes a solid, metastatic, and invasive neoplasm, but this is forgotten when leukemia is viewed as only a "liquid" cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs